Pasritamig vs. best supportive care in metastatic castrate resistant prostate cancer

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T cell redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer.

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T cell redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer.

For More Information:

https://clinicaltrials.gov/study/NCT07164443?term=NCT07164443&rank=1